On Mar. 11, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to evaluate the safety of fostamatinib, Rigel’s oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients.

The study was sponsored by the National Heart, Lung, and Blood Institute in collaboration with Inova Health System. The Phase 2 clinical trial wasconducted at the NIH Clinical Center in Bethesda, Maryland, the nation’s largest hospital devoted entirely to clinical research, and Inova Fairfax Hospital.